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AUTHOR'S SUMMARY
Although lipid-lowering therapy has become a mainstay in preventive cardiology, many 
people do not realize how individual's genetic information and current genetic knowledge 
can be used in clinical practice. Genetic testing is one of the methods to find etiology in 
monogenic or polygenic dyslipidemia. Pharmacogenetic data may provide guidance for 
selection of treatment-eligible patients and lipid-lowering therapeutics. In addition, recent 
progress in research regarding genetics, bioinformatics, and pharmacological platforms 
accelerated drug target discovery and drug development in the field of dyslipidemia and 
cardiovascular disease prevention. 
ABSTRACT
Dyslipidemia is a strong risk factor for cardiovascular disease as well as a major target for 
its prevention. Along with the progress in genetic research techniques and bioinformatics 
analysis, genetic knowledge helps manage individuals with dyslipidemia. Familial 
hypercholesterolemia, the most common monogenic lipid disorder, can be diagnosed 
clinically without confirming pathogenic mutations. However, it can be difficult to do so 
due to uncertain family history, and genetic testing is of vital importance in such cases. 
Conversely, recent studies have revealed that combination effect of rare and common variants 
is frequent in people with other extreme lipid phenotypes. Genetic characteristics are helpful 
for prediction and selection of patients with high risk for cardiovascular disease or poor 
response to lipid-lowering therapy. In the past decade, studies using new genetic techniques 
have identified novel associations among lipid metabolism-associated genes, intermediate 
lipid phenotypes, and cardiovascular health. Such findings shed light on new drug targets. 
With improvements in the platforms and processes for drug development, several recent 
clinical trials showed promising results regarding lipid control and potential cardiovascular 
disease prevention.
Keywords: Atherosclerosis; Genomics; Hypertriglyceridemia; Genetic therapy; 
Hypercholesterolemia
Korean Circ J. 2021 Nov;51(11):899-907
https://doi.org/10.4070/kcj.2021.0239
pISSN 1738-5520·eISSN 1738-5555
State of the Art Review
Received: Jul 19, 2021
Accepted: Jul 25, 2021
Correspondence to
Sang-Hak Lee, MD, PhD
Division of Cardiology, Department of 
Internal Medicine, Severance Hospital, Yonsei 
University College of Medicine, 50-1, Yonsei-ro, 
Seodaemun-gu, Seoul 03722, Korea.
E-mail: shl1106@yuhs.ac
Copyright © 2021. The Korean Society of 
Cardiology
This is an Open Access article distributed 
under the terms of the Creative Commons 
Attribution Non-Commercial License (https://
creativecommons.org/licenses/by-nc/4.0) 
which permits unrestricted noncommercial 
use, distribution, and reproduction in any 






This work was supported by the National 
Research Foundation of Korea, funded 
by the Korean government (grant No. 
2019R1F1A1057952).
Conflict of Interest
The authors have no financial conflicts of 
interest.
Data Sharing Statement
The data generated in this study is available 
from the corresponding author(s) upon 
reasonable request.
Sang-Hak Lee , MD, PhD 
Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of 
Medicine, Seoul, Korea
Role of Genetics in Preventive 
Cardiology: Focused on Dyslipidemia
INTRODUCTION
In the past three decades, lipid management has become a mainstay of primary and 
secondary pharmacological cardiovascular prevention. Many studies have evaluated and 
validated several cardiovascular risk factors, including age, high low-density lipoprotein 
cholesterol (LDL-C), low high-density lipoprotein cholesterol (HDL-C), high triglycerides, 
and inflammation.1) Pharmacological agents have been developed to control these risk 
factors, and some have shown good efficacy. However, only a few originally developed agents 
have achieved the final goal of reducing the risk for cardiovascular disease. As mentioned, the 
most well-known controllable risk factor with clinical benefit is high LDL-C, and the most 
successful pharmacological approach is lipid-lowering, particularly with statins.2)
Since around 2010, genetic studies using new techniques began to report novel associations 
among human genes, intermediate phenotypes such as lipid profile, and cardiovascular risk. 
Interestingly, a considerable proportion of vascular disease-associated genetic signals is 
linked to biological pathways relevant to traditional risk factors.3) These findings indicate that 
diagnosis and treatment of patients with dyslipidemia and as well as investigation of new risk 
factors and treatment targets are critical issues.
Here, I present the role of genetics in care of patients with dyslipidemia and in cardiovascular 
disease prevention. Particularly, its role in diagnosis, personalized treatment, and drug 
discovery and development is discussed.
GENETICS FOR DIAGNOSIS OF FAMILIAL 
HYPERCHOLESTEROLEMIA
Familial hypercholesterolemia (FH) is the most frequent monogenic autosomal dominant 
disorder that causes premature coronary artery disease. Patients with FH are generally diagnosed 
by clinical criteria after active suspicion by physicians.4)5) Several clinical criteria including 
Dutch, Simon Broome, and Make Early Diagnosis to Prevent Early Death criteria are being used. 
Diagnosis by such criteria is based on cholesterol levels, physical findings, history of vascular 
disease, and family history of hypercholesterolemia or premature coronary artery disease. 
However, there are limitations in clinical diagnosis of FH because it is frequently difficult to 
obtain sufficient data essential for FH diagnosis from patients. When we encounter a patient 
with vascular disease who is receiving lipid-lowering therapy (LLT), it can be hard to assess their 
lipid profile without pharmacotherapy after sufficient wash-out of medications. It can be difficult 
or impossible to get exact information regarding physical findings, onset age of coronary artery 
disease, or pre-treatment cholesterol levels of family members. In this regard, genetic testing is 
not only useful, but also essential for diagnosis in some patients suspicious of FH.
Genetic screening and interpretation of FH testing can be performed in several ways, as 
depicted in Figure 1. One method is serial single-gene testing (sequential gene testing, that 
evaluates LDLR, the most common causative gene in FH, and checks for any deletion or 
duplication. Thereafter, APOB and PCSK9 are sequenced. However, after cost-reduction in 
testing such as next-generation sequencing, it is possible to screen relevant mutations with 
lower cost and higher efficiency. LDLR, APOB, PCSK9, and other lipid-associated genes can 
be included in a single panel (multi-gene testing). Such sequencing can uncover: known 
pathogenic mutations, novel mutations, or no monogenic pathogenic mutations. After 
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identifying a novel mutation, it is necessary to determine its functionality. Methods for 
this are familial cosegregation, in silico analysis, and in vitro experiment. In an example of 
cosegregation in a family with FH,6, the proband (red arrow), a 48-year-old man, showed a 
D834Rfs/- heterozygous mutation (Figure 2A and B). A sister of the proband had an affected 
phenotype with the same mutation, whereas his 2 children's cholesterol levels were not 
elevated, and they did not have the mutation (Figure 2A and B). Conversely, diverse public 
genetic data can help provide an appropriate decision about the pathogenicity of a mutation, 
even when its functionality has not been proven.
GENETICS FOR PATIENTS WITH OTHER EXTREME LIPID 
PHENOTYPES
Screening of genetic variants and proteins associated with lipid metabolism in patients with 
extreme lipid phenotypes has been used to discover targets influencing clinical outcomes.7) 
In previous studies, we analyzed rare and common genetic variants in Koreans with extreme 
lipid phenotypes. After screening more than 10,000 patients, 22 whose LDL-C levels without 
LLT were below the first percentile (48 mg/dL) of the Korean population were analyzed. Two 
target genes, APOB and PCSK9, which are major contributors to the hypobetalipoproteinemia 
phenotype, were sequenced. In this study, rare variants of APOB or PCSK9 were identified in 














Figure 1. Flow of genetic testing for diagnosis of familial hypercholesterolemia. Any of the sequential or multi-gene testing methods can be used to identify 
pathogenic mutations. When novel mutations are found, their functionality can be examined through familial cosegregation, in silico analysis, or in vitro 





















Figure 2. Example of familial cosegregation of a potential pathogenic mutation. (A) Pedigree shows people whose DNA was examined. The proband (P05), 
proband's sister (P05-F01), proband's daughter (P05-F02), and proband's son (P05-F03) were included. (B) The cholesterol levels of the proband and his sister 
were compatible with FH, whereas his 2 children had normal levels. Sanger sequencing revealed the same heterozygous mutation in the proband and his 
sister, whereas no mutations were present in his children (from Han et al.6)). The study including this figure was approved by the Institutional Review Board of 
Severance Hospital, Seoul, Korea (No. 4-2008-0267) and the participants gave written informed consent.
In another study, 26 patients with very high triglyceride level (885 mg/dL [10 mmol/L]) 
were selected. Five candidate genes, LPL, APOC2, GPIHBP1, APOA5, and LMF1, relevant to 
triglyceride lipolysis were sequenced. In the analysis, rare homozygous variants of the five 
genes were very uncommon, while rare heterozygous variants were frequently identified 
(Figure 3B).9) Conversely, 42 subjects with HDL-C level greater than 100 mg/dL were analyzed 
for three target genes, CETP, LIPC, and SCARB1. Two rare variants of CETP were found in 13 
patients, and one rare variant of SCARB1 was found in a single subject. All subjects had at least 
one of four common CETP or LIPC variants (Figure 3C).10)
Testing result for monogenic and pathogenic variants in individuals with an extreme lipid 
phenotype is often negative. Most cases in this population are thought to be manifesting 
the combined effects of rare heterozygous and common variants of lipid-related genes. 
Understanding the effects of genetic variants associated with extreme lipid phenotype can 
provide insight into its potential therapeutic targets as well as its pathophysiology.
GENETICS FOR PERSONALIZED TREATMENT OF 
DYSLIPIDEMIA AND CARDIOVASCULAR PREVENTION
As the therapeutic strategy for patients with FH and pathogenic mutations is the same as for 
those without mutations, many physicians are skeptical about performing genetic tests in 
individuals suspicious of FH. However, genetic information is helpful for determining which 
FH patient is at higher risk for cardiovascular disease and thus who needs more aggressive LLT. 
In a Japanese study, patients with the FH phenotype and pathogenic monogenic mutations 
showed about three times higher cardiovascular risk than those without mutations.11)
In addition, knowledge regarding an individual's genetic characteristics can allow prediction 
of patients with poor response to LLT. Patients with FH and null mutations have shown 
higher cholesterol levels and lower rates of target achievement.12)13) In a large Spanish study, 
the presence of defective mutations was a predictor of the ability to reach goal cholesterol 
levels.14) In our previous study, patients without pathogenic mutations showed better 
achievement in LDL-C reduction following a statin/ezetimibe-based regimen.15) Furthermore, 
















































Figure 3. The prevalence of rare and common variant carriers in populations with 3 extreme lipid phenotypes. (A) Carriers of APOB or PCSK9 variants in people with 
very low low-density lipoprotein cholesterol level (from Lee et al.8)). (B) Carriers of LPL, APOC2, GPIHBP1, APOA5, or LMF1 variants in people with very high triglyceride 
levels (from Lee et al.).9) (C) Carriers of CETP, LIPC, or SCARB1 variant in people with very high high-density lipoprotein cholesterol levels (from Lee et al.).10)
defective mutations compared to those with null mutations. Interestingly, this finding was 
also observed in patients with homozygous FH (Figure 4).15)
Researchers have tried to identify specific genes and their variants to predict response to LLT 
and to use these results in personalized therapeutic approaches. Recent high-throughput 
studies have identified genetic loci that are associated with response to LLT. A metagenome-
wide association study using more than 18,000 patients confirmed that four loci close to SORT1/
CLESR2/PSRC1, LPA, SLCO1B1, and APOE were linked to the response to statins.16) A study coined 
a genetic score based on 57 SNPs associated with coronary artery disease and showed that it 
was correlated with clinical benefit of statins.17) Although data including those of the above-
mentioned studies are not sufficient for active clinical use, further research on this issue can 
suggest a more refined clue to individualized LLT. Taken together, information regarding an 
individual's genetic characteristics is helpful for selection of patients that require more active 
treatment, prediction of drug response, and choice for more appropriate LLT regimen.
GENETICS FOR DRUG TARGET DISCOVERY AND 
DEVELOPMENT
The progression of technologies related to genomic research and collected data in the past 
decade have imparted opportunity to discover drug targets. For researchers, high throughput 
sequencing and genome-wide association studies have been available since the late 2000s; 
they have continuously gotten less expensive since around 2010. At the same time, great 
advances in bioinformatic analysis techniques have provided tools to identify genes and 
variants positively or negatively associated with extreme lipid traits and cardiovascular risk.18) 




























































Figure 4. Achievement of expected LDL-C reduction through evolocumab treatment in patients with FH. Blue 
bars indicate LDL-C reduction following addition of evolocumab to the statin/ezetimibe regimen. Orange bars 
indicate the achievement of expected LDL-C reduction (adjusted lipid-lowering response) following addition of 
evolocumab to the statin/ezetimibe regimen. Differences in LDL-C reduction and adjusted response are observed 
according to mutation type, irrespective of disease homozygosity (From Kim et al.15)). 
CNV = copy number variation; FH = familial hypercholesterolemia; HeFH = heterozygous familial hypercholesterolemia; 
HoFH = homozygous familial hypercholesterolemia; LDL-C = low-density lipoprotein cholesterol.
uncover unbiased, causal relationships among lipid levels, cardiovascular phenotypes, and 
rare genetic variants, via so-called “Mendelian randomization study.”19-21) This kind of work 
was not possible in older studies that used target approaches or simple association analyses 
realized by traditional techniques and relatively small budgets. These new-generation studies 
in the field of dyslipidemia and cardiovascular prevention report on the genes related to 
lipolysis and their clinical impact (Figure 5).22) Studies investigating the relationship between 
hypotriglyceridemia or combined hypolipidemia and ANGPTL3,23) APOC3,19) or ANGPTL4 
24) (all linked to lipoprotein lipase activity) have shed light on development of therapeutics 
targeting these genes or gene-related products.
Furthermore, techniques to develop therapeutics to target specific genes, such as antisense 
oligonucleotides, have become more refined (Figure 6).25) In addition, a few antibody-based 

























Figure 5. LPL and other related proteins supporting or inhibiting this enzyme acting in endothelial cells 
(from Olivecrona with permission20)). In the last decade, some of these genes and their proteins have shown 
considerable influence on the risk of coronary artery disease, suggesting a causal effect. 
ANGPTL = angiopoietin-like protein; ECM = extracellular matrix; FFA = free fatty acid; HSPG = heparan sulfate 
proteoglycan; GPIHBP1 = glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1; LMF1 = lipase 
maturation factor 1; LPL = lipoprotein lipase; Sel1L = sel-1 suppressor of lin-12-like 1; TRL = triglyceride-rich lipoprotein.
Table 1. Summary of recent drug studies based on genetic discovery regarding dyslipidemia
Drug name Evolocumab25) & alirocumab Volanesorsen26) Evinacumab24)
Target gene or protein PCSK9 APOC3 ANGPTL3
Platform Humanized monoclonal antibodies Antisense oligonucleotides Humanized monoclonal antibody
Stage Approved worldwide Approved to treat familial chylomicronemia  
in some European countries
Approved for HoFH treatment in the 
United States
Major effects More than 50% LDL-C reduction on 
top of statin
Greater than 70% TG reduction Greater than 50 and 46% LDL-C and TG 
reductions, respectively, on top of statin & 
PCSK9 inhibitors
Strengths & limitations Effective in LDL-C lowering and CV 
risk reduction; long-term safety not 
available
First agent for familial chylomicronemia 
treatment; no outcome studies; 
Thrombocytopenia
Simultaneous reduction of LDL-C & TG; no 
outcome studies
CV = cardiovascular; HoFH = homozygous familial hypercholesterolemia; LDL-C = low-density lipoprotein cholesterol; TG = triglycerides.
demonstrate some powerful pharmacological agents based on genetic knowledge and their 
clinical impact in the field of lipid management and cardiovascular prevention.27)28)
CONCLUSION
Genetic testing is useful for diagnosis and risk assessment of patients with FH, a 
representative monogenic lipid disorder. Genetic studies help us to understand etiology of 
other extreme lipid phenotypes. Although in its early stage, pharmacogenetic data provide 
guidance for selection of treatment-eligible patients and optimal lipid-lowering therapeutics. 
Recent progress in genetic research, bioinformatics analysis, and pharmacological platforms 
increased the efficiency of discovery of drug targets and development of novel therapeutics.
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